Dr. Shilpa Tekula, MD, is a medical director at Novartis Pharmaceuticals, where she plays a pivotal role in U.S. oncology medical affairs. A physician-scientist with a background in pathology, she began her career in clinical academia before moving into industry to expand her impact on patient care beyond the microscope.
Tekula’s career reflects growth across every level of medical affairs. As a field-based medical science liaison, she advanced scientific engagement while working to close care gaps for patients in underserved communities, including Native American populations. By building trust and expanding access to breast cancer education, Tekula helped bridge disparities that extended far beyond clinical data. Building on this foundation, she later served as product team lead for early breast cancer, where she shaped postlaunch strategy by ensuring real-world field insights were translated into meaningful action.
Today, Tekula contributes to U.S. medical strategy in radioligand therapy (RLT), one of the most promising oncology platforms in solid tumors. Her leadership spans clinical strategy, evidence generation and research collaborations—all aimed at addressing unmet needs and advancing outcomes for patients. Tekula’s journey and contributions were spotlighted in a professionally produced Novartis video, showcased at both U.S. and global medical affairs meetings, and even submitted to the Cannes Lions Awards.
Recognized with Novartis’ prestigious President’s Club Award, Tekula continues to challenge the status quo, proving that scientific rigor and empathy together drive meaningful change. A cancer survivor, first-generation Indian-American and mother, she champions equity, authenticity and mentorship for the next generation of leaders in oncology.